Treatment use in 13 countries in 410 patients, grouped by GDP/capita
| Overall (N=410) | Patients in lowest country GDP/capita tertile (N=101) | Patients in middle country GDP/capita tertile (N=180) | Patients in highest country GDP/capita tertile (N=129) | P value between the tertiles | |
| bDMARDs use, n (%) | 250 (61.0) | 54 (53.5) | 113 (62.8) | 83 (64.3) | 0.197 |
| csDMARDs use, n (%) | 237 (61.4) | 67 (72.8) | 93 (54.7) | 77 (62.1) | 0.016 |
| Methotrexate use, n (%) | 200 (52.2) | 57 (63.3) | 79 (46.5) | 64 (52.0) | 0.035 |
| Oral glucocorticoids use, n (%) | 64 (17.5) | 21 (25.6) | 19 (11.6) | 24 (20.0) | 0.016 |
| High or moderate disease activity (DAPSA >14) and no bDMARD use, n (%) | 76 (18.5) | 30 (29.7) | 27 (15.0) | 19 (14.7) | 0.004* |
Lowest country GDP/capita tertile: Brazil, Turkey, Russian Federation, Romania, Estonia; middle tertile: Spain, Italy, UK, France; highest tertile: Canada, Germany, USA and Singapore.
Data were missing for glucocorticoids (n=44), csDMARDs (n=24) and methotrexate (n=27). Percentages are percentages of available data.
*Specific comparisons were made between tertiles: lowest vs middle (p=0.009), lowest vs highest (p=0.007), middle vs highest (p=0.882).
bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic DMARDs; DAPSA, Disease Activity in PSoriatic Arthritis; GDP, gross domestic product.